在基于顺铂化疗的胸腺瘤和胸腺癌患者中,依

SCI

GapsinGuideline-ConcordantUseofDiagnosticTestsAmongLungCancerPatients

目的

Noeffectivesalvagetreatmentsareavailableforpatientswithadvanced/recurrentthymoma(T)orthymiccarcinoma(TC)whohaveprogressedafterplatinum-basedchemotherapy.Thisstudyevaluatedtheactivityofeverolimusinpatientswithadvanced/recurrentTorTCpreviouslytreatedwithcisplatin-containingchemotherapy.

对于那些在铂类化疗后又发生进展的晚期/复发胸腺瘤（T）或胸腺癌（TC）的患者，没有有效的治疗方法。这项研究评估了everolimus对以前曾使用过顺式化疗药物治疗过的晚期/复发T或TC的效果。

方法

Thiswasasingle-arm,single-stage,open-label,multicenter,phaseIItrial.Patientsreceivedoraleverolimus10mg/duntildiseaseprogression,unacceptabletoxicity,orpatientrefusal.AFlemingphaseIItrialwasdesigned.Thenullhypothesisofatruediseasecontrolrate(DCR)of40%wastestedagainstaone-sidedalternativeofatrueDCRof60%(α=β=0.10):Ifdiseasecontrolwereachievedin≥21ofthefirst41evaluablepatients,everolimuscouldbere

转载请注明：http://www.ldkhr.com/yfzl/10521.html